Targeting GMC Oxidoreductase with High Affinity Small Molecules for Reducing Patulin Production.

Flavine adenine dinucleotide (FAD) dependent glucose methanol choline oxidoreductase (GMC oxidoreductase) is the terminal key enzyme of the patulin biosynthetic pathway. GMC oxidoreductase catalyzes the oxidative ring closure of ()-ascladiol to patulin. Currently, no protein involved in the patulin biosynthesis in has been experimentally characterized or solved by X-ray diffraction. Consequently, nothing is known about GMC oxidoreductase substrate-binding site and mode of action. In the present investigation, a 3D comparative model for GMC oxidoreductase has been described. Furthermore, a multistep computational approach was used to identify GMC oxidoreductase residues involved in the FAD binding and in substrate recognition. Notably, the obtained 3D comparative model of GMC oxidoreductase was used for performing a virtual screening of a chemical/drug library, which allowed to predict new GMC oxidoreductase high affinity ligands to be tested in in vitro/in vivo assays. In vitro assays performed in presence of 6-hydroxycoumarin and meticrane, among the highly affinity predicted binders, confirmed a dose-dependent inhibition (17-81%) of patulin production by 6-hydroxycoumarin (10 µM-1 mM concentration range), whereas the approved drug meticrane inhibited patulin production by 43% already at 10 µM. Furthermore, 6-hydroxycoumarin and meticrane caused a 60 and 41% reduction of patulin production, respectively, in vivo on apples at 100 µg/wound.